IDH1 and central nervous system cancer: Moreover, patients with IDH1 wild-type high-grade gliomas harboring BRAF or NF1 mutations and receiving trametinib monotherapy or in combination with dabrafenib had longer progression-free and overall survival than patients who did not receive genotype-matched targeted therapy (20).